Reuters
Share:
On 24 February 2022, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions recommending a change to the terms of the marketing authorisation for the medicinal products Delstrigo and Pifeltro.
The CHMP adopted an extension to the existing indications as follows:
Related HIV and Co-Infections News
-
TheBodyPro: Can long-acting regimens solve virologic failure in heavily treatment-experienced people with HIV?
-
[Press release] TaiMed Biologics completes Phase 2b enrollment for TMB-365/380 in HIV maintenance therapy study
-
Spotlight: South Africa’s ARV programme hardly grew in 2025, according to latest estimates
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.